

TEAE by Preferred Term - with fisher's exact test p-value

Safety Analysis Set

Copyright @ mycsg.in

Preferred Term	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)	Low dose vs Placebo p-value [1]
Overall	65 (75.6%)	77 (91.7%)	76 (90.5%)	0.0065
ABDOMINAL DISCOMFORT	0	0	1 (1.2%)	-
ABDOMINAL PAIN	1 (1.2%)	3 (3.6%)	1 (1.2%)	0.3647
ACROCHORDON EXCISION	0	0	1 (1.2%)	-
ACTINIC KERATOSIS	0	0	1 (1.2%)	-
AGITATION	2 (2.3%)	2 (2.4%)	1 (1.2%)	1.0000
ALCOHOL USE	0	0	1 (1.2%)	-
ALLERGIC GRANULOMATOUS ANGIITIS	0	0	1 (1.2%)	-
ALOPECIA	1 (1.2%)	0	0	1.0000
AMNESIA	0	0	1 (1.2%)	-
ANXIETY	0	3 (3.6%)	0	0.1184
APPLICATION SITE BLEEDING	0	1 (1.2%)	0	0.4941
APPLICATION SITE DERMATITIS	5 (5.8%)	9 (10.7%)	7 (8.3%)	0.2767
APPLICATION SITE DESQUAMATION	0	1 (1.2%)	0	0.4941
APPLICATION SITE DISCHARGE	0	0	1 (1.2%)	-
APPLICATION SITE DISCOLOURATION	0	1 (1.2%)	0	0.4941
APPLICATION SITE ERYTHEMA	3 (3.5%)	12 (14.3%)	15 (17.9%)	0.0152
APPLICATION SITE INDURATION	1 (1.2%)	0	0	1.0000
APPLICATION SITE IRRITATION	3 (3.5%)	9 (10.7%)	9 (10.7%)	0.0783

TFL

[1] Fisher's exact test.

TEAE by Preferred Term - with fisher's exact test p-value

Safety Analysis Set

Copyright @ mycsg.in

Preferred Term	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)	Low dose vs Placebo p-value [1]
APPLICATION SITE PAIN	0	0	2 (2.4%)	-
APPLICATION SITE PERSPIRATION	0	0	2 (2.4%)	-
APPLICATION SITE PRURITUS	6 (7.0%)	22 (26.2%)	22 (26.2%)	0.0008
APPLICATION SITE REACTION	1 (1.2%)	0	1 (1.2%)	1.0000
APPLICATION SITE SWELLING	0	1 (1.2%)	2 (2.4%)	0.4941
APPLICATION SITE URTICARIA	0	2 (2.4%)	1 (1.2%)	0.2427
APPLICATION SITE VESICLES	1 (1.2%)	4 (4.8%)	6 (7.1%)	0.2077
APPLICATION SITE WARMTH	0	1 (1.2%)	0	0.4941
ARTHRALGIA	1 (1.2%)	2 (2.4%)	1 (1.2%)	0.6183
ARTHRITIS	0	0	1 (1.2%)	-
ASTHENIA	1 (1.2%)	0	1 (1.2%)	1.0000
ATRIAL FIBRILLATION	1 (1.2%)	1 (1.2%)	3 (3.6%)	1.0000
ATRIAL FLUTTER	0	1 (1.2%)	1 (1.2%)	0.4941
ATRIAL HYPERTROPHY	1 (1.2%)	0	0	1.0000
ATRIOVENTRICULAR BLOCK FIRST DEGREE	1 (1.2%)	1 (1.2%)	0	1.0000
ATRIOVENTRICULAR BLOCK SECOND DEGREE	1 (1.2%)	0	0	1.0000
BACK PAIN	1 (1.2%)	1 (1.2%)	3 (3.6%)	1.0000
BALANCE DISORDER	0	1 (1.2%)	0	0.4941
BENIGN PROSTATIC HYPERPLASIA	1 (1.2%)	0	1 (1.2%)	1.0000
BIOPSY	0	0	1 (1.2%)	-

TFL

[1] Fisher's exact test.

TEAE by Preferred Term - with fisher's exact test p-value

Safety Analysis Set

Copyright @ mycsg.in

Preferred Term	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)	Low dose vs Placebo p-value [1]
BIOPSY PROSTATE	0	0	1 (1.2%)	-
BLISTER	0	5 (6.0%)	1 (1.2%)	0.0277
BLOOD ALKALINE PHOSPHATASE INCREASED	1 (1.2%)	0	0	1.0000
BLOOD CHOLESTEROL INCREASED	0	0	1 (1.2%)	-
BLOOD CREATINE PHOSPHOKINASE INCREASED	1 (1.2%)	0	0	1.0000
BLOOD GLUCOSE INCREASED	0	1 (1.2%)	1 (1.2%)	0.4941
BLOOD URINE PRESENT	1 (1.2%)	0	0	1.0000
BODY TEMPERATURE INCREASED	0	1 (1.2%)	0	0.4941
BRADYCARDIA	1 (1.2%)	0	0	1.0000
BRONCHITIS	1 (1.2%)	0	0	1.0000
BUNDLE BRANCH BLOCK LEFT	1 (1.2%)	0	0	1.0000
BUNDLE BRANCH BLOCK RIGHT	1 (1.2%)	1 (1.2%)	0	1.0000
BURNING SENSATION	0	0	2 (2.4%)	-
CALCULUS URETHRAL	0	0	1 (1.2%)	-
CARDIAC DISORDER	0	0	1 (1.2%)	-
CARDIAC FAILURE CONGESTIVE	1 (1.2%)	0	0	1.0000
CATARACT OPERATION	1 (1.2%)	1 (1.2%)	0	1.0000
CELLULITIS	0	1 (1.2%)	0	0.4941
CERUMEN IMPACTION	0	1 (1.2%)	0	0.4941
CERVICITIS	1 (1.2%)	0	0	1.0000

TFL

[1] Fisher's exact test.

TEAE by Preferred Term - with fisher's exact test p-value

Safety Analysis Set

Copyright @ mycsg.in

Preferred Term	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)	Low dose vs Placebo p-value [1]
CHEST DISCOMFORT	0	0	2 (2.4%)	-
CHEST PAIN	0	0	2 (2.4%)	-
CHILLS	1 (1.2%)	1 (1.2%)	1 (1.2%)	1.0000
COGNITIVE DISORDER	0	0	1 (1.2%)	-
COLD SWEAT	1 (1.2%)	0	0	1.0000
COLON CANCER	0	1 (1.2%)	0	0.4941
COMPLETED SUICIDE	1 (1.2%)	0	0	1.0000
COMPLEX PARTIAL SEIZURES	0	1 (1.2%)	0	0.4941
CONFUSIONAL STATE	2 (2.3%)	3 (3.6%)	1 (1.2%)	0.6800
CONJUNCTIVAL HAEMORRHAGE	0	1 (1.2%)	0	0.4941
CONJUNCTIVITIS	1 (1.2%)	0	0	1.0000
CONSTIPATION	1 (1.2%)	0	0	1.0000
CONTUSION	1 (1.2%)	1 (1.2%)	2 (2.4%)	1.0000
COORDINATION ABNORMAL	0	1 (1.2%)	0	0.4941
COUGH	1 (1.2%)	5 (6.0%)	5 (6.0%)	0.1152
CYSTITIS	1 (1.2%)	0	1 (1.2%)	1.0000
CYSTOSCOPY	1 (1.2%)	0	0	1.0000
DECREASED APPETITE	1 (1.2%)	0	1 (1.2%)	1.0000
DEHYDRATION	1 (1.2%)	0	0	1.0000
DELIRIUM	0	0	1 (1.2%)	-

TFL

[1] Fisher's exact test.

TEAE by Preferred Term - with fisher's exact test p-value

Safety Analysis Set

Copyright @ mycsg.in

Preferred Term	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)	Low dose vs Placebo p-value [1]
DELUSION	1 (1.2%)	0	1 (1.2%)	1.0000
DEPRESSED MOOD	0	1 (1.2%)	0	0.4941
DERMATITIS CONTACT	0	1 (1.2%)	0	0.4941
DIABETES MELLITUS	1 (1.2%)	0	0	1.0000
DIARRHOEA	9 (10.5%)	4 (4.8%)	4 (4.8%)	0.2482
DISORIENTATION	1 (1.2%)	0	0	1.0000
DIZZINESS	2 (2.3%)	8 (9.5%)	11 (13.1%)	0.0556
DRUG ERUPTION	1 (1.2%)	0	0	1.0000
DYSPEPSIA	1 (1.2%)	1 (1.2%)	0	1.0000
DYSPHAGIA	0	1 (1.2%)	0	0.4941
DYSPHONIA	0	1 (1.2%)	0	0.4941
DYSPNOEA	1 (1.2%)	1 (1.2%)	1 (1.2%)	1.0000
DYSURIA	1 (1.2%)	1 (1.2%)	0	1.0000
EAR INFECTION	2 (2.3%)	0	0	0.4971
EAR PAIN	1 (1.2%)	0	0	1.0000
ELECTROCARDIOGRAM ST SEGMENT DEPRESSION	4 (4.7%)	1 (1.2%)	0	0.3677
ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED	1 (1.2%)	1 (1.2%)	0	1.0000
ELECTROCARDIOGRAM T WAVE INVERSION	2 (2.3%)	1 (1.2%)	1 (1.2%)	1.0000
EMPHYSEMA	1 (1.2%)	0	0	1.0000

TFL

[1] Fisher's exact test.

TEAE by Preferred Term - with fisher's exact test p-value

Safety Analysis Set

Copyright @ mycsg.in

Preferred Term	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)	Low dose vs Placebo p-value [1]
EPISTAXIS	0	1 (1.2%)	2 (2.4%)	0.4941
ERYTHEMA	8 (9.3%)	14 (16.7%)	14 (16.7%)	0.1754
EXCORIATION	2 (2.3%)	1 (1.2%)	1 (1.2%)	1.0000
EYE ALLERGY	1 (1.2%)	0	0	1.0000
EYE LASER SURGERY	1 (1.2%)	0	0	1.0000
EYE PRURITUS	1 (1.2%)	0	0	1.0000
EYE SWELLING	1 (1.2%)	0	0	1.0000
FACIAL BONES FRACTURE	0	0	1 (1.2%)	-
FALL	1 (1.2%)	2 (2.4%)	1 (1.2%)	0.6183
FATIGUE	1 (1.2%)	5 (6.0%)	5 (6.0%)	0.1152
FEELING ABNORMAL	0	0	1 (1.2%)	-
FEELING COLD	0	0	1 (1.2%)	-
FLANK PAIN	0	0	1 (1.2%)	-
FLATULENCE	1 (1.2%)	0	0	1.0000
FOOD CRAVING	1 (1.2%)	1 (1.2%)	0	1.0000
GASTROENTERITIS VIRAL	1 (1.2%)	0	0	1.0000
GASTROINTESTINAL HAEMORRHAGE	0	0	1 (1.2%)	-
GASTROOESOPHAGEAL REFLUX DISEASE	1 (1.2%)	0	0	1.0000
GLOSSITIS	1 (1.2%)	0	0	1.0000
HAEMOPTYSIS	1 (1.2%)	0	0	1.0000

TFL

[1] Fisher's exact test.

TEAE by Preferred Term - with fisher's exact test p-value

Safety Analysis Set

Copyright @ mycsg.in

Preferred Term	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)	Low dose vs Placebo p-value [1]
HALLUCINATION	0	0	1 (1.2%)	-
HALLUCINATION, VISUAL	0	0	1 (1.2%)	-
HEADACHE	3 (3.5%)	3 (3.6%)	5 (6.0%)	1.0000
HEART RATE INCREASED	1 (1.2%)	0	0	1.0000
HEART RATE IRREGULAR	1 (1.2%)	0	0	1.0000
HEMIANOPIA HOMONYMOUS	0	1 (1.2%)	0	0.4941
HIATUS HERNIA	1 (1.2%)	0	0	1.0000
HIP FRACTURE	1 (1.2%)	0	2 (2.4%)	1.0000
HORDEOLUM	0	0	1 (1.2%)	-
HOT FLUSH	0	1 (1.2%)	0	0.4941
HYPERBILIRUBINAEMIA	1 (1.2%)	0	0	1.0000
HYPERHIDROSIS	2 (2.3%)	4 (4.8%)	8 (9.5%)	0.4406
HYPERSENSITIVITY	0	1 (1.2%)	0	0.4941
HYPERSOMNIA	0	0	1 (1.2%)	-
HYPERTENSION	1 (1.2%)	1 (1.2%)	0	1.0000
HYPONATRAEMIA	1 (1.2%)	0	0	1.0000
HYPOTENSION	2 (2.3%)	1 (1.2%)	0	1.0000
INCONTINENCE	0	1 (1.2%)	0	0.4941
INCREASED APPETITE	1 (1.2%)	0	1 (1.2%)	1.0000
INFLAMMATION	0	1 (1.2%)	0	0.4941

TFL

[1] Fisher's exact test.

TEAE by Preferred Term - with fisher's exact test p-value

Safety Analysis Set

Copyright @ mycsg.in

Preferred Term	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)	Low dose vs Placebo p-value [1]
INFLUENZA	1 (1.2%)	1 (1.2%)	1 (1.2%)	1.0000
INSOMNIA	2 (2.3%)	0	2 (2.4%)	0.4971
IRRITABILITY	1 (1.2%)	1 (1.2%)	0	1.0000
JOINT DISLOCATION	0	1 (1.2%)	0	0.4941
LETHARGY	0	1 (1.2%)	1 (1.2%)	0.4941
LIBIDO DECREASED	0	0	1 (1.2%)	-
LISTLESS	0	0	1 (1.2%)	-
LOCALISED INFECTION	1 (1.2%)	0	0	1.0000
LOWER RESPIRATORY TRACT INFECTION	0	0	1 (1.2%)	-
MALAISE	0	1 (1.2%)	2 (2.4%)	0.4941
MALIGNANT FIBROUS HISTIOCYTOMA	0	1 (1.2%)	0	0.4941
MICTURITION URGENCY	1 (1.2%)	1 (1.2%)	1 (1.2%)	1.0000
MUSCLE SPASMS	0	1 (1.2%)	1 (1.2%)	0.4941
MUSCULAR WEAKNESS	0	1 (1.2%)	0	0.4941
MYALGIA	0	0	1 (1.2%)	-
MYOCARDIAL INFARCTION	4 (4.7%)	2 (2.4%)	4 (4.8%)	0.6820
NASAL CONGESTION	3 (3.5%)	1 (1.2%)	3 (3.6%)	0.6206
NASAL MUCOSA BIOPSY	0	1 (1.2%)	0	0.4941
NASOPHARYNGITIS	2 (2.3%)	4 (4.8%)	6 (7.1%)	0.4406
NAUSEA	3 (3.5%)	3 (3.6%)	6 (7.1%)	1.0000

TFL

[1] Fisher's exact test.

TEAE by Preferred Term - with fisher's exact test p-value

Safety Analysis Set

Copyright @ mycsg.in

Preferred Term	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)	Low dose vs Placebo p-value [1]
NEPHROLITHIASIS	1 (1.2%)	0	1 (1.2%)	1.0000
NIGHTMARE	0	0	1 (1.2%)	-
OEDEMA	0	2 (2.4%)	0	0.2427
OEDEMA PERIPHERAL	2 (2.3%)	1 (1.2%)	2 (2.4%)	1.0000
ORTHOSTATIC HYPOTENSION	1 (1.2%)	0	0	1.0000
PAIN	0	1 (1.2%)	1 (1.2%)	0.4941
PAIN IN EXTREMITY	1 (1.2%)	0	0	1.0000
PALPITATIONS	0	2 (2.4%)	0	0.2427
PARAESTHESIA	0	0	1 (1.2%)	-
PARAESTHESIA ORAL	0	1 (1.2%)	0	0.4941
PARKINSON'S DISEASE	1 (1.2%)	0	0	1.0000
PAROSMIA	0	0	1 (1.2%)	-
PARTIAL SEIZURES WITH SECONDARY GENERALISATION	0	0	1 (1.2%)	-
PELVIC PAIN	1 (1.2%)	0	0	1.0000
PHARYNGEAL ERYTHEMA	0	0	1 (1.2%)	-
PHARYNGOLARYNGEAL PAIN	0	1 (1.2%)	1 (1.2%)	0.4941
PNEUMONIA	0	1 (1.2%)	0	0.4941
POLLAKIURIA	1 (1.2%)	0	0	1.0000
POSTNASAL DRIP	1 (1.2%)	0	0	1.0000

TFL

[1] Fisher's exact test.

TEAE by Preferred Term - with fisher's exact test p-value

Safety Analysis Set

Copyright @ mycsg.in

Preferred Term	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)	Low dose vs Placebo p-value [1]
PRODUCTIVE COUGH	0	0	1 (1.2%)	-
PROSTATE CANCER	0	0	1 (1.2%)	-
PRURITUS	8 (9.3%)	21 (25.0%)	26 (31.0%)	0.0078
PRURITUS GENERALISED	0	1 (1.2%)	1 (1.2%)	0.4941
PSYCHOMOTOR HYPERACTIVITY	1 (1.2%)	0	0	1.0000
PYREXIA	2 (2.3%)	0	1 (1.2%)	0.4971
RALES	1 (1.2%)	0	0	1.0000
RASH	5 (5.8%)	13 (15.5%)	9 (10.7%)	0.0480
RASH ERYTHEMATOUS	0	1 (1.2%)	0	0.4941
RASH MACULO-PAPULAR	0	0	1 (1.2%)	-
RASH PRURITIC	0	1 (1.2%)	2 (2.4%)	0.4941
RECTAL HAEMORRHAGE	0	1 (1.2%)	0	0.4941
RESPIRATORY TRACT CONGESTION	0	0	1 (1.2%)	-
RESTLESSNESS	0	1 (1.2%)	0	0.4941
RHINITIS	0	0	1 (1.2%)	-
RHINORRHOEA	0	1 (1.2%)	1 (1.2%)	0.4941
SALIVARY HYPERSECRETION	0	0	4 (4.8%)	-
SECRETION DISCHARGE	0	1 (1.2%)	0	0.4941
SHOULDER PAIN	1 (1.2%)	2 (2.4%)	0	0.6183
SINUS ARRHYTHMIA	1 (1.2%)	0	0	1.0000

TFL

[1] Fisher's exact test.

TEAE by Preferred Term - with fisher's exact test p-value

Safety Analysis Set

Copyright @ mycsg.in

Preferred Term	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)	Low dose vs Placebo p-value [1]
SINUS BRADYCARDIA	2 (2.3%)	7 (8.3%)	8 (9.5%)	0.0971
SKIN EXFOLIATION	0	1 (1.2%)	0	0.4941
SKIN IRRITATION	3 (3.5%)	6 (7.1%)	5 (6.0%)	0.3261
SKIN LACERATION	1 (1.2%)	2 (2.4%)	0	0.6183
SKIN LESION EXCISION	0	0	1 (1.2%)	-
SKIN ODOUR ABNORMAL	0	0	1 (1.2%)	-
SKIN ULCER	1 (1.2%)	0	0	1.0000
SOMNOLENCE	2 (2.3%)	3 (3.6%)	1 (1.2%)	0.6800
STOMACH DISCOMFORT	0	0	1 (1.2%)	-
STUPOR	0	1 (1.2%)	0	0.4941
SUDDEN DEATH	0	1 (1.2%)	0	0.4941
SUPRAVENTRICULAR EXTRASYSTOLES	1 (1.2%)	1 (1.2%)	1 (1.2%)	1.0000
SUPRAVENTRICULAR TACHYCARDIA	0	1 (1.2%)	0	0.4941
SWELLING	0	1 (1.2%)	0	0.4941
SYNCOPE	0	4 (4.8%)	3 (3.6%)	0.0575
SYNCOPE VASOVAGAL	0	0	1 (1.2%)	-
TACHYCARDIA	1 (1.2%)	0	0	1.0000
TRANSIENT ISCHAEMIC ATTACK	0	2 (2.4%)	1 (1.2%)	0.2427
ULCER	0	1 (1.2%)	0	0.4941
UPPER RESPIRATORY TRACT INFECTION	6 (7.0%)	1 (1.2%)	3 (3.6%)	0.1174

TFL

[1] Fisher's exact test.

TEAE by Preferred Term - with fisher's exact test p-value

Safety Analysis Set

Copyright @ mycsg.in

Preferred Term	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)	Low dose vs Placebo p-value [1]
URINARY TRACT INFECTION	2 (2.3%)	0	1 (1.2%)	0.4971
URTICARIA	0	1 (1.2%)	1 (1.2%)	0.4941
VAGINAL MYCOSIS	1 (1.2%)	0	0	1.0000
VENTRICULAR EXTRASYSTOLES	0	2 (2.4%)	1 (1.2%)	0.2427
VENTRICULAR HYPERTROPHY	1 (1.2%)	0	0	1.0000
VENTRICULAR SEPTAL DEFECT	0	1 (1.2%)	2 (2.4%)	0.4941
VERTIGO	0	1 (1.2%)	1 (1.2%)	0.4941
VIRAL INFECTION	0	1 (1.2%)	0	0.4941
VISION BLURRED	0	1 (1.2%)	1 (1.2%)	0.4941
VOMITING	3 (3.5%)	3 (3.6%)	7 (8.3%)	1.0000
WEIGHT DECREASED	0	0	1 (1.2%)	-
WOLFF-PARKINSON-WHITE SYNDROME	0	1 (1.2%)	0	0.4941
WOUND	0	1 (1.2%)	0	0.4941
WOUND HAEMORRHAGE	0	0	1 (1.2%)	-

TFL

[1] Fisher's exact test.